MiMedx Group, Inc (NASDAQ:MDXG) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of MiMedx Group, Inc (NASDAQ:MDXG) have been assigned a consensus recommendation of “Moderate Buy” from the five ratings firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $9.50.

A number of equities research analysts have recently commented on MDXG shares. Lake Street Capital cut their price objective on MiMedx Group from $12.00 to $10.00 and set a “buy” rating for the company in a research report on Tuesday, January 20th. Wall Street Zen raised MiMedx Group from a “buy” rating to a “strong-buy” rating in a report on Sunday, November 2nd. UBS Group set a $10.00 price target on MiMedx Group in a research note on Monday. Cantor Fitzgerald cut their price objective on MiMedx Group from $12.00 to $8.00 and set an “overweight” rating on the stock in a report on Tuesday, February 17th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of MiMedx Group in a report on Monday, December 29th.

Institutional Trading of MiMedx Group

Large investors have recently added to or reduced their stakes in the company. Divisadero Street Capital Management LP increased its position in MiMedx Group by 362.9% in the 2nd quarter. Divisadero Street Capital Management LP now owns 223,220 shares of the company’s stock worth $1,364,000 after purchasing an additional 175,000 shares during the last quarter. Hussman Strategic Advisors Inc. bought a new stake in shares of MiMedx Group in the 3rd quarter valued at approximately $1,759,000. Trigran Investments Inc. raised its position in MiMedx Group by 10.4% during the second quarter. Trigran Investments Inc. now owns 8,390,458 shares of the company’s stock valued at $51,266,000 after acquiring an additional 790,901 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in MiMedx Group in the second quarter valued at approximately $268,000. Finally, SG Americas Securities LLC grew its position in MiMedx Group by 419.3% in the third quarter. SG Americas Securities LLC now owns 161,960 shares of the company’s stock worth $1,130,000 after acquiring an additional 130,769 shares in the last quarter. 79.15% of the stock is owned by institutional investors and hedge funds.

MiMedx Group Stock Down 0.6%

NASDAQ MDXG opened at $5.17 on Monday. MiMedx Group has a 12 month low of $4.89 and a 12 month high of $8.46. The company has a market capitalization of $765.68 million, a P/E ratio of 19.15 and a beta of 1.59. The company’s 50 day simple moving average is $5.89 and its 200 day simple moving average is $6.64. The company has a debt-to-equity ratio of 0.07, a current ratio of 4.41 and a quick ratio of 3.95.

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.